

Special Issue 'Molecular Detection and Typing of Viruses'.

Ilka Engelmann

▶ To cite this version:

Ilka Engelmann. Special Issue 'Molecular Detection and Typing of Viruses'.. Diagnostics, 2021, Diagnostics, 11 (11), pp.2031. 10.3390/diagnostics11112031. hal-04448670

HAL Id: hal-04448670 https://hal.univ-lille.fr/hal-04448670

Submitted on 9 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.








Editorial

Special Issue "Molecular Detection and Typing of Viruses"

Ilka Engelmann 🗅



I thank all authors, reviewers and the editorial staff who contributed to this special issue. The articles published in this special issue highlight how molecular biology has revolutionized virology. Molecular biology is nowadays largely used for virus detection in routine diagnosis, for virus typing and phylogenetic analysis. It is also useful for the discovery of new viruses that may be pathogens or members of our healthy virome. An example of how central the role of molecular biology has become to virology, is a recently discovered virus that became a public health concern, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus was first identified by next generation sequencing [1]. One article in this special issue addresses the challenges of discovering new viruses by using next generation sequencing [2]. Following the spread of SARS-CoV-2 that rapidly caused a pandemic, it was then searched for and detected massively by reverse-transcription polymerase chain reaction (RT PCR). At first, laboratory developed assays became available, the first ones already in January 2020, only two weeks after the announcement of the novel coronavirus as causative pathogen of pneumonia [3]. Then, a wealth of commercial assays were developed. A study published in this special issue [4] applied RT PCR to different specimen types. This allowed to characterize spatio-temporal virus load dynamics of this new virus and shed some light on the pathophysiology of the infection, termed COVID-19 [4]. Molecular assays for detection of SARS-CoV-2 variants have next been developed to screen for variants of concern, with one example being published in this special issue [5]. Lately, next generation sequencing has become widely used to track down new variants and follow the evolution of this new virus [6]. Two other reports in this special issue describe the use of molecular biology techniques applied to phylogenetic studies and typing of hepatitis C and influenza A viruses, respectively [7,8]. Last but not least, molecular biology also is the basis of most of the currently available vaccines against SARS-CoV-2, that are either RNA based or viral vector based [9]. Taken together, this shows that we can no longer conceive virology without molecular biology.

November 2021

Funding: This research received no external funding.

Conflicts of Interest: The author declares no conflict of interest.



Citation: Engelmann, I. Special Issue "Molecular Detection and Typing of Viruses". *Diagnostics* **2021**, *11*, 2031. https://doi.org/10.3390/diagnostics11112031

Received: 1 October 2021 Accepted: 14 October 2021 Published: 3 November 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Diagnostics **2021**, 11, 2031 2 of 2

References

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China. N. Engl. J. Med. 2020, 382, 727–733. [CrossRef] [PubMed]

- 2. Folgueiras-González, A.; van den Braak, R.; Deijs, M.; van der Hoek, L.; de Groof, A. A Versatile Processing Workflow to Enable Pathogen Detection in Clinical Samples from Organs Using VIDISCA. *Diagnostics* **2021**, *11*, 791. [CrossRef] [PubMed]
- 3. Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L.; et al. Detection of 2019 Novel Coronavirus (2019-NCoV) by Real-Time RT-PCR. *Eurosurveillance* 2020, 25, 2000045. [CrossRef] [PubMed]
- 4. Alidjinou, E.K.; Poissy, J.; Ouafi, M.; Caplan, M.; Benhalima, I.; Goutay, J.; Tinez, C.; Faure, K.; Chopin, M.C.; Yelnik, C.; et al. Spatial and Temporal Virus Load Dynamics of SARS-CoV-2. *Diagnostics* **2021**, *11*, 427. [CrossRef] [PubMed]
- 5. Nörz, D.; Grunwald, M.; Tang, H.T.; Olearo, F.; Günther, T.; Robitaille, A.; Fischer, N.; Grundhoff, A.; Aepfelbacher, M.; Pfefferle, S.; et al. Rapid automated screening for SARS-CoV-2 B.1.617 lineage 2 variants (delta/kappa) through a versatile toolset of qPCR-3 based SNP detection. *Diagnostics* **2021**, *11*, 1818. [CrossRef] [PubMed]
- 6. Oude Munnink, B.B.; Worp, N.; Nieuwenhuijse, D.F.; Sikkema, R.S.; Haagmans, B.; Fouchier, R.A.M.; Koopmans, M. The next phase of SARS-CoV-2 surveillance: Real-time molecular epidemiology. *Nat. Med.* **2021**, 27, 1518–1524. [CrossRef] [PubMed]
- 7. Ebranati, E.; Mancon, A.; Airoldi, M.; Renica, S.; Shkjezi, R.; Dragusha, P.; Della Ventura, C.; Ciccaglione, A.R.; Ciccozzi, M.; Bino, S.; et al. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe. *Diagnostics* **2021**, *11*, 327. [CrossRef] [PubMed]
- 8. Lin, Q.; Ji, X.; Wu, F.; Ma, L. Conserved Sequence Analysis of Influenza A Virus HA Segment and Its Application in Rapid Typing. *Diagnostics* **2021**, *11*, 1328. [CrossRef] [PubMed]
- 9. WHO. *COVID-19 Vaccine Tracker and Landscape*; WHO: Geneva, Switzerland, 2021. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed on 1 October 2021).